IBDEI3AJ ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,52519,2)
;;=^5002633
;;^UTILITY(U,$J,358.3,52520,0)
;;=E11.3211^^194^2540^22
;;^UTILITY(U,$J,358.3,52520,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52520,1,3,0)
;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
;;^UTILITY(U,$J,358.3,52520,1,4,0)
;;=4^E11.3211
;;^UTILITY(U,$J,358.3,52520,2)
;;=^5138331
;;^UTILITY(U,$J,358.3,52521,0)
;;=E11.3212^^194^2540^23
;;^UTILITY(U,$J,358.3,52521,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52521,1,3,0)
;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
;;^UTILITY(U,$J,358.3,52521,1,4,0)
;;=4^E11.3212
;;^UTILITY(U,$J,358.3,52521,2)
;;=^5138332
;;^UTILITY(U,$J,358.3,52522,0)
;;=E11.3213^^194^2540^24
;;^UTILITY(U,$J,358.3,52522,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52522,1,3,0)
;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
;;^UTILITY(U,$J,358.3,52522,1,4,0)
;;=4^E11.3213
;;^UTILITY(U,$J,358.3,52522,2)
;;=^5138333
;;^UTILITY(U,$J,358.3,52523,0)
;;=E11.40^^194^2540^10
;;^UTILITY(U,$J,358.3,52523,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52523,1,3,0)
;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
;;^UTILITY(U,$J,358.3,52523,1,4,0)
;;=4^E11.40
;;^UTILITY(U,$J,358.3,52523,2)
;;=^5002644
;;^UTILITY(U,$J,358.3,52524,0)
;;=E11.51^^194^2540^12
;;^UTILITY(U,$J,358.3,52524,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52524,1,3,0)
;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
;;^UTILITY(U,$J,358.3,52524,1,4,0)
;;=4^E11.51
;;^UTILITY(U,$J,358.3,52524,2)
;;=^5002650
;;^UTILITY(U,$J,358.3,52525,0)
;;=E11.52^^194^2540^11
;;^UTILITY(U,$J,358.3,52525,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52525,1,3,0)
;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
;;^UTILITY(U,$J,358.3,52525,1,4,0)
;;=4^E11.52
;;^UTILITY(U,$J,358.3,52525,2)
;;=^5002651
;;^UTILITY(U,$J,358.3,52526,0)
;;=E11.620^^194^2540^5
;;^UTILITY(U,$J,358.3,52526,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52526,1,3,0)
;;=3^DM Type 2 w/ Diab Dermatitis
;;^UTILITY(U,$J,358.3,52526,1,4,0)
;;=4^E11.620
;;^UTILITY(U,$J,358.3,52526,2)
;;=^5002655
;;^UTILITY(U,$J,358.3,52527,0)
;;=E11.36^^194^2540^4
;;^UTILITY(U,$J,358.3,52527,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52527,1,3,0)
;;=3^DM Type 2 w/ Diab Cataract
;;^UTILITY(U,$J,358.3,52527,1,4,0)
;;=4^E11.36
;;^UTILITY(U,$J,358.3,52527,2)
;;=^5002642
;;^UTILITY(U,$J,358.3,52528,0)
;;=I10.^^194^2541^1
;;^UTILITY(U,$J,358.3,52528,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52528,1,3,0)
;;=3^Essential/Primary Hypertension
;;^UTILITY(U,$J,358.3,52528,1,4,0)
;;=4^I10.
;;^UTILITY(U,$J,358.3,52528,2)
;;=^5007062
;;^UTILITY(U,$J,358.3,52529,0)
;;=I11.0^^194^2541^12
;;^UTILITY(U,$J,358.3,52529,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52529,1,3,0)
;;=3^Hypertensive Heart Disease w/ Heart Failure
;;^UTILITY(U,$J,358.3,52529,1,4,0)
;;=4^I11.0
;;^UTILITY(U,$J,358.3,52529,2)
;;=^5007063
;;^UTILITY(U,$J,358.3,52530,0)
;;=I11.9^^194^2541^13
;;^UTILITY(U,$J,358.3,52530,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52530,1,3,0)
;;=3^Hypertensive Heart Disease w/o Heart Failure
;;^UTILITY(U,$J,358.3,52530,1,4,0)
;;=4^I11.9
;;^UTILITY(U,$J,358.3,52530,2)
;;=^5007064
;;^UTILITY(U,$J,358.3,52531,0)
;;=I12.0^^194^2541^5
;;^UTILITY(U,$J,358.3,52531,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,52531,1,3,0)
;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3AJ 3761 printed Apr 09, 2024@21:56:33 Page 2
IBDEI3AJ ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,52519,2)
+2 ;;=^5002633
+3 ;;^UTILITY(U,$J,358.3,52520,0)
+4 ;;=E11.3211^^194^2540^22
+5 ;;^UTILITY(U,$J,358.3,52520,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,52520,1,3,0)
+8 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
+9 ;;^UTILITY(U,$J,358.3,52520,1,4,0)
+10 ;;=4^E11.3211
+11 ;;^UTILITY(U,$J,358.3,52520,2)
+12 ;;=^5138331
+13 ;;^UTILITY(U,$J,358.3,52521,0)
+14 ;;=E11.3212^^194^2540^23
+15 ;;^UTILITY(U,$J,358.3,52521,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,52521,1,3,0)
+18 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
+19 ;;^UTILITY(U,$J,358.3,52521,1,4,0)
+20 ;;=4^E11.3212
+21 ;;^UTILITY(U,$J,358.3,52521,2)
+22 ;;=^5138332
+23 ;;^UTILITY(U,$J,358.3,52522,0)
+24 ;;=E11.3213^^194^2540^24
+25 ;;^UTILITY(U,$J,358.3,52522,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,52522,1,3,0)
+28 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
+29 ;;^UTILITY(U,$J,358.3,52522,1,4,0)
+30 ;;=4^E11.3213
+31 ;;^UTILITY(U,$J,358.3,52522,2)
+32 ;;=^5138333
+33 ;;^UTILITY(U,$J,358.3,52523,0)
+34 ;;=E11.40^^194^2540^10
+35 ;;^UTILITY(U,$J,358.3,52523,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,52523,1,3,0)
+38 ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
+39 ;;^UTILITY(U,$J,358.3,52523,1,4,0)
+40 ;;=4^E11.40
+41 ;;^UTILITY(U,$J,358.3,52523,2)
+42 ;;=^5002644
+43 ;;^UTILITY(U,$J,358.3,52524,0)
+44 ;;=E11.51^^194^2540^12
+45 ;;^UTILITY(U,$J,358.3,52524,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,52524,1,3,0)
+48 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
+49 ;;^UTILITY(U,$J,358.3,52524,1,4,0)
+50 ;;=4^E11.51
+51 ;;^UTILITY(U,$J,358.3,52524,2)
+52 ;;=^5002650
+53 ;;^UTILITY(U,$J,358.3,52525,0)
+54 ;;=E11.52^^194^2540^11
+55 ;;^UTILITY(U,$J,358.3,52525,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,52525,1,3,0)
+58 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
+59 ;;^UTILITY(U,$J,358.3,52525,1,4,0)
+60 ;;=4^E11.52
+61 ;;^UTILITY(U,$J,358.3,52525,2)
+62 ;;=^5002651
+63 ;;^UTILITY(U,$J,358.3,52526,0)
+64 ;;=E11.620^^194^2540^5
+65 ;;^UTILITY(U,$J,358.3,52526,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,52526,1,3,0)
+68 ;;=3^DM Type 2 w/ Diab Dermatitis
+69 ;;^UTILITY(U,$J,358.3,52526,1,4,0)
+70 ;;=4^E11.620
+71 ;;^UTILITY(U,$J,358.3,52526,2)
+72 ;;=^5002655
+73 ;;^UTILITY(U,$J,358.3,52527,0)
+74 ;;=E11.36^^194^2540^4
+75 ;;^UTILITY(U,$J,358.3,52527,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,52527,1,3,0)
+78 ;;=3^DM Type 2 w/ Diab Cataract
+79 ;;^UTILITY(U,$J,358.3,52527,1,4,0)
+80 ;;=4^E11.36
+81 ;;^UTILITY(U,$J,358.3,52527,2)
+82 ;;=^5002642
+83 ;;^UTILITY(U,$J,358.3,52528,0)
+84 ;;=I10.^^194^2541^1
+85 ;;^UTILITY(U,$J,358.3,52528,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,52528,1,3,0)
+88 ;;=3^Essential/Primary Hypertension
+89 ;;^UTILITY(U,$J,358.3,52528,1,4,0)
+90 ;;=4^I10.
+91 ;;^UTILITY(U,$J,358.3,52528,2)
+92 ;;=^5007062
+93 ;;^UTILITY(U,$J,358.3,52529,0)
+94 ;;=I11.0^^194^2541^12
+95 ;;^UTILITY(U,$J,358.3,52529,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,52529,1,3,0)
+98 ;;=3^Hypertensive Heart Disease w/ Heart Failure
+99 ;;^UTILITY(U,$J,358.3,52529,1,4,0)
+100 ;;=4^I11.0
+101 ;;^UTILITY(U,$J,358.3,52529,2)
+102 ;;=^5007063
+103 ;;^UTILITY(U,$J,358.3,52530,0)
+104 ;;=I11.9^^194^2541^13
+105 ;;^UTILITY(U,$J,358.3,52530,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,52530,1,3,0)
+108 ;;=3^Hypertensive Heart Disease w/o Heart Failure
+109 ;;^UTILITY(U,$J,358.3,52530,1,4,0)
+110 ;;=4^I11.9
+111 ;;^UTILITY(U,$J,358.3,52530,2)
+112 ;;=^5007064
+113 ;;^UTILITY(U,$J,358.3,52531,0)
+114 ;;=I12.0^^194^2541^5
+115 ;;^UTILITY(U,$J,358.3,52531,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,52531,1,3,0)
+118 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
